Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.36 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 15/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL3785728 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL31567979 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL678417 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL28432235 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL11467778 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL10797449 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL5092309 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL28639090 | 1.00 | KIF11 (0.55) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3784063 | 0.98 | KIF11 (0.57) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6653059 | 0.98 | KIF11 (0.57) | KIF11KCNH2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115888674-A | Uranium adsorption material and preparation method and application thereof | 核工业北京化工冶金研究院 | 2023-04-04 | — | — | CN | claimed |
| US-9522915-B2 | Method for preparing an important intermediate of linagliptin | 2Y-CHEM, LTD. (CN) | 2016-12-20 | — | — | US | claimed |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | 2Y-CHEM, LTD. (CN) | 2015-10-01 | — | — | US | claimed |
| EP-2563375-B1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | ALCON RES LTD (US) | 2014-06-25 | — | — | EP | claimed |
| US-20140080793-A1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | ALCON RESEARCH, LTD. (US) | 2014-03-20 | — | — | US | claimed |
| EP-2563375-A1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | Alcon Research, Ltd. (US) | 2013-03-06 | — | — | EP | claimed |
| US-20110269719-A1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | ALCON RESEARCH, LTD. | 2011-11-03 | — | — | US | claimed |
| WO-2011137090-A1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | ALCON RESEARCH, LTD. (US) | 2011-11-03 | — | — | WO | claimed |
| CN-115888674-B | Uranium adsorption material, preparation method and application thereof | 核工业北京化工冶金研究院 | 2024-12-20 | — | — | CN | disclosed |
| US-11919998-B2 | Polycarbonate polyol nanocomposites | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2024-03-05 | — | — | US | disclosed |
| CN-116640426-A | Vermiculite PBAT antibacterial composite film and preparation method thereof | 贵州民族大学 | 2023-08-25 | — | — | CN | disclosed |
| CN-115888674-A | Uranium adsorption material and preparation method and application thereof | 核工业北京化工冶金研究院 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022153234-A1 | POLYCARBONATE POLYOL NANOCOMPOSITES | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2022-07-21 | — | — | WO | disclosed |
| US-20220227924-A1 | POLYCARBONATE POLYOL NANOCOMPOSITES | SAUDI ARAMCO TECH CO (SA) | 2022-07-21 | — | — | US | disclosed |
| US-20090043024-A1 | POLYCARBONATE NANOCOMPOSITES | GENERAL ELECTRIC COMPANY (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008091413-A2 | POLYCARBONATE COMPOSITION COMPRISING NANOMATERIALS | SABIC INNOVATIVE PLASTICS BV (US) | 2008-07-31 | — | — | WO | disclosed |
| US-20080167414-A1 | a nanocomposite mixture of aromatic polycarbonates and silica, clays, talc or alumina nanostructure particles, used in the preparation of articles by injection molding or extrusion | CITIBANK, N.A., AS COLLATERAL AGENT | 2008-07-10 | — | — | US | disclosed |
| WO-2008042496-A1 | METHOD OF MAKING POLYCARBONATE NANOCOMPOSITES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-04-10 | — | — | WO | disclosed |
| US-20080081865-A1 | METHOD OF MAKING POLYCARBONATE NANOCOMPOSITES | CITIBANK, N.A., AS COLLATERAL AGENT | 2008-04-03 | — | — | US | disclosed |
| US-4537848-A | Positively charged toner compositions containing phosphonium charge enhancing additives | XEROX CORPORATION (US) | 1985-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269719-A1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | PHOSPHO1, EYA3, EYA2 | SIGMAR1 1846/4885CHRM2 4701/4885CHRM3 4442/4885 |
| US-20140080793-A1 | PHARMACEUTICAL COMPOSITIONS WITH PHOSPHONIUM ANTIMICROBIAL AGENTS | PHOSPHO1, EYA3, EYA2 | SIGMAR1 1846/4885CHRM2 4701/4885CHRM3 4442/4885 |
| US-20150274728-A1 | METHOD FOR PREPARING AN IMPORTANT INTERMEDIATE OF LINAGLIPTIN | DPP4, DPP9, DPP3 | SIGMAR1 3933/4885CHRM2 4759/4885CHRM3 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.